Drug intelligence / Profile preview

AV078

Development stage: Phase 2
Lead developer: Aeovian Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AV078 is a central nervous system-penetrant, selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1), currently in Phase 1 clinical development for the treatment of epilepsy associated with tuberous sclerosis complex (TSC). It is a small molecule drug designed to modulate the mTORC1 pathway, which plays a critical role in cell growth and proliferation. AV078 aims to provide improved efficacy and safety compared to existing mTOR inhibitors by selectively targeting mTORC1. The drug is being developed by Aeovian Pharmaceuticals[1][2][3][5][7].

Other names: av-078av078av 078

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on AV078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV078.

Explore the full profile